-
1.发明申请Pharmaceutical compositions comprising a selective I1 imidazoline receptor agonist and an angiotensin II receptor blocker 审中-公开包含选择性I 1咪唑啉受体激动剂和血管紧张素II受体阻断剂的药物组合物公开(公告)号：US20050143435A1
公开(公告)日：2005-06-30
申请号：US10959317
申请日：2004-10-07
IPC分类号： A61K31/4172 , A61K31/4178 , A61K31/4184 , A61K31/506 , A61K45/06
CPC分类号： A61K45/06 , A61K31/4178 , A61K31/506 , A61K2300/00
摘要： Parmaceutical compositions comprising selective imidazoline receptor agonists combined with angiotensin II receptor blockers, particularly, pharmaceutical compositions comprising Moxonidine and Eprosartan mesylate, as well as the use of such compositions for the treatment of hypertension, especially in hypertensive patients suffering from type II diabetes or susceptible to developing type II diabetes.
摘要翻译： 包含与血管紧张素II受体阻断剂组合的选择性咪唑啉受体激动剂的药物组合物，特别是包含莫西尼定和甲磺酸依普罗沙坦的药物组合物，以及这些组合物用于治疗高血压的用途，特别是在患有II型糖尿病的高血压患者中 发展II型糖尿病。
-
2.发明授权Pancreatin micropellets prepared with polyethylene glycol 4000, paraffin and a lower alcohol by extrusion and rounding 失效用聚乙二醇4000，石蜡和低级醇通过挤出和四舍五入制备胰蛋白酶微丸
公开(公告)号：US5378462A
公开(公告)日：1995-01-03
申请号：US109051
申请日：1993-08-19
申请人： Bernd Boedecker , Friederike Henninges , Klaus-Juergen Koelln , Guenther Kuhnow , Guenter-Josef Peschke , Manfred Rehburg , Alwin Sobe , Berthold Stemmle
发明人： Bernd Boedecker , Friederike Henninges , Klaus-Juergen Koelln , Guenther Kuhnow , Guenter-Josef Peschke , Manfred Rehburg , Alwin Sobe , Berthold Stemmle
IPC分类号： A61J3/07 , A61K9/16 , A61K9/36 , A61K9/50 , A61K38/46 , A61K38/54 , A61K37/62 , A01N25/34 , C12N11/08 , C12N11/18
CPC分类号： A61K9/1694 , A61K9/1641 , A61K9/5042
摘要： Pancreatin-containing micropellet cores which can be coated with a gastric juice-resistant film are prepared by extruding a mixture containing pancreatin, polyethylene glycol 4000 and a lower alcohol such as propan-2-ol to produce extrudates which break by themselves into fragments, rounding the fragments with the addition of highly liquid paraffin and drying. Propan-2-ol may be present with the paraffin during rounding. The micropellet cores contain 65-85% pancreatin, and have a bulk density of 0.6 g/ml to 0.85 g/ml, a spherical to ellipsoidal shape with a minor axis in the range of 0.7-1.4 mm and a particle size distribution in which at least 80% of the micropellet cores have a minor axis to major axis ratio in the range from 1:1 to 1:2.
摘要翻译： 通过挤压含有胰酶，聚乙二醇4000和低级醇如丙-2-醇的混合物制备可涂覆有耐胃酸膜的含胰蛋白酶的微丸芯，制备出自己断裂成碎片的挤出物 片中加入高度液体石蜡并干燥。 丙烯醇可能在四舍五入期间与石蜡一起存在。 微丸芯含有65-85％的胰酶，其体积密度为0.6g / ml至0.85g / ml，球形至椭圆形的短轴为0.7-1.4mm，粒径分布为 至少80％的微芯线芯具有在1：1至1：2的长轴比的短轴。
-
3.发明申请Pharmaceutical Compositions Comprising a Selective I1 Imidazoline Receptor Agonist and an Angiotensin II Receptor Blocker 审中-公开包含选择性I1咪唑啉受体激动剂和血管紧张素II受体阻断剂的药物组合物公开(公告)号：US20110229571A1
公开(公告)日：2011-09-22
申请号：US13116620
申请日：2011-05-26
IPC分类号： A61K9/30 , A61K31/513 , A61K31/421 , A61K31/4184 , A61K31/4178 , A61K31/41 , A61K9/20 , A61K9/28 , A61K31/5415 , A61P3/06 , A61P3/00 , A61P3/10 , A61P9/04 , A61P13/12 , A61P9/12 , A61P7/10
CPC分类号： A61K45/06 , A61K31/4178 , A61K31/506 , A61K2300/00
摘要： Pharmaceutical compositions containing selective imidazoline receptor agonists combined with angiotensin II receptor blockers, particularly, pharmaceutical compositions containing Moxonidine and Eprosartan mesylate, as well as the use of such compositions for the treatment of hypertension, especially in hypertensive patients suffering from type II diabetes or susceptible to developing type II diabetes.
摘要翻译： 包含与血管紧张素II受体阻断剂联合的选择性咪唑啉受体激动剂的药物组合物，特别是含有莫索尼定和甲磺酸依普罗沙坦的药物组合物，以及这些组合物用于治疗高血压的用途，特别是在患有II型糖尿病的高血压患者中 发展II型糖尿病。
-
4.发明授权公开(公告)号：US08802087B2
公开(公告)日：2014-08-12
申请号：US11085073
申请日：2005-03-22
CPC分类号： A61K38/54 , A61K9/1075 , A61K9/1617 , A61K9/1641 , A61K31/22 , A61K31/745 , A61K38/465 , A61K38/47 , A61K38/48 , A61K2300/00
摘要： Orally administrable pharmaceutical compositions of lipase-containing products, particularly pancreatin and pancreatin-containing products, or of enzyme products which contain at least one lipase of non-animal, especially microbial origin, which improve the lipolytic activity and particularly result in stabilization of the lipase in the acidic pH range. These oral pharmaceutical compositions contain a system which includes at least one surfactant and one co-surfactant and optionally a lipophilic phase, and are self-emulsifiable on contact with a hydrophilic and a lipophilic phase. The compositions according to the invention are suitable for treating or inhibiting maldigestion, especially maldigestion due to chronic exocrine pancreatic insufficiency, in mammals and humans.
摘要翻译： 含有脂肪酶的产品，特别是胰酶和含胰酶的产品的口服给药的药物组合物，或含有至少一种非动物，特别是微生物来源的脂肪酶的酶产品，其可改善脂肪分解活性并特别导致脂肪酶稳定 在酸性pH范围内。 这些口服药物组合物含有包含至少一种表面活性剂和一种辅助表面活性剂和任选的亲油相的系统，并且在亲水相和亲油相接触时是自乳化的。 根据本发明的组合物适用于治疗或抑制哺乳动物和人类的消化不良，特别是由于慢性外分泌胰腺功能不全引起的消化不良。
-
5.发明申请公开(公告)号：US20050250817A1
公开(公告)日：2005-11-10
申请号：US11085073
申请日：2005-03-22
CPC分类号： A61K38/54 , A61K9/1075 , A61K9/1617 , A61K9/1641 , A61K31/22 , A61K31/745 , A61K38/465 , A61K38/47 , A61K38/48 , A61K2300/00
摘要： Orally administrable pharmaceutical compositions of lipase-containing products, particularly pancreatin and pancreatin-containing products, or of enzyme products which contain at least one lipase of non-animal, especially microbial origin, which improve the lipolytic activity and particularly result in stabilization of the lipase in the acidic pH range. These oral pharmaceutical compositions contain a system which includes at least one surfactant and one co-surfactant and optionally a lipophilic phase, and are self-emulsifiable on contact with a hydrophilic and a lipophilic phase. The compositions according to the invention are suitable for treating or inhibiting maldigestion, especially maldigestion due to chronic exocrine pancreatic insufficiency, in mammals and humans.
摘要翻译： 含有脂肪酶的产品，特别是胰酶和含胰酶的产品的口服给药的药物组合物，或含有至少一种非动物，特别是微生物来源的脂肪酶的酶产品，其可改善脂肪分解活性并特别导致脂肪酶稳定 在酸性pH范围内。 这些口服药物组合物含有包含至少一种表面活性剂和一种辅助表面活性剂和任选的亲油相的系统，并且在亲水相和亲油相接触时是自乳化的。 根据本发明的组合物适用于治疗或抑制哺乳动物和人类的消化不良，特别是由于慢性外分泌胰腺功能不全引起的消化不良。
-
-
-
-
搜索结果
5 条记录 (耗时 0.012 秒)
